390 related articles for article (PubMed ID: 18625725)
1. Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.
Wang SE; Xiang B; Guix M; Olivares MG; Parker J; Chung CH; Pandiella A; Arteaga CL
Mol Cell Biol; 2008 Sep; 28(18):5605-20. PubMed ID: 18625725
[TBL] [Abstract][Full Text] [Related]
2. Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton.
Wang SE; Xiang B; Zent R; Quaranta V; Pozzi A; Arteaga CL
Cancer Res; 2009 Jan; 69(2):475-82. PubMed ID: 19147560
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility.
Ueda Y; Wang S; Dumont N; Yi JY; Koh Y; Arteaga CL
J Biol Chem; 2004 Jun; 279(23):24505-13. PubMed ID: 15044465
[TBL] [Abstract][Full Text] [Related]
4. Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Hutcheson IR; Knowlden JM; Hiscox SE; Barrow D; Gee JM; Robertson JF; Ellis IO; Nicholson RI
Breast Cancer Res; 2007; 9(4):R50. PubMed ID: 17686159
[TBL] [Abstract][Full Text] [Related]
5. FOXO1A is a target for HER2-overexpressing breast tumors.
Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
[TBL] [Abstract][Full Text] [Related]
6. Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells.
Joshi JP; Brown NE; Griner SE; Nahta R
Biochem Pharmacol; 2011 Nov; 82(9):1090-9. PubMed ID: 21803025
[TBL] [Abstract][Full Text] [Related]
7. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.
Esteva FJ; Guo H; Zhang S; Santa-Maria C; Stone S; Lanchbury JS; Sahin AA; Hortobagyi GN; Yu D
Am J Pathol; 2010 Oct; 177(4):1647-56. PubMed ID: 20813970
[TBL] [Abstract][Full Text] [Related]
8. HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.
Gijsen M; King P; Perera T; Parker PJ; Harris AL; Larijani B; Kong A
PLoS Biol; 2010 Dec; 8(12):e1000563. PubMed ID: 21203579
[TBL] [Abstract][Full Text] [Related]
9. PI3K inhibition overcomes trastuzumab resistance: blockade of ErbB2/ErbB3 is not always enough.
Hynes NE; Dey JH
Cancer Cell; 2009 May; 15(5):353-5. PubMed ID: 19411062
[TBL] [Abstract][Full Text] [Related]
10. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
11. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.
Ghosh R; Narasanna A; Wang SE; Liu S; Chakrabarty A; Balko JM; González-Angulo AM; Mills GB; Penuel E; Winslow J; Sperinde J; Dua R; Pidaparthi S; Mukherjee A; Leitzel K; Kostler WJ; Lipton A; Bates M; Arteaga CL
Cancer Res; 2011 Mar; 71(5):1871-82. PubMed ID: 21324925
[TBL] [Abstract][Full Text] [Related]
13. A small-molecule inhibitor of SMAD3 attenuates resistance to anti-HER2 drugs in HER2-positive breast cancer cells.
Chihara Y; Shimoda M; Hori A; Ohara A; Naoi Y; Ikeda JI; Kagara N; Tanei T; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Nov; 166(1):55-68. PubMed ID: 28702892
[TBL] [Abstract][Full Text] [Related]
14. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.
O'Brien NA; Browne BC; Chow L; Wang Y; Ginther C; Arboleda J; Duffy MJ; Crown J; O'Donovan N; Slamon DJ
Mol Cancer Ther; 2010 Jun; 9(6):1489-502. PubMed ID: 20501798
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
16. Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells.
Marty B; Maire V; Gravier E; Rigaill G; Vincent-Salomon A; Kappler M; Lebigot I; Djelti F; Tourdès A; Gestraud P; Hupé P; Barillot E; Cruzalegui F; Tucker GC; Stern MH; Thiery JP; Hickman JA; Dubois T
Breast Cancer Res; 2008; 10(6):R101. PubMed ID: 19055754
[TBL] [Abstract][Full Text] [Related]
17. TACE-mediated ectodomain shedding of the type I TGF-beta receptor downregulates TGF-beta signaling.
Liu C; Xu P; Lamouille S; Xu J; Derynck R
Mol Cell; 2009 Jul; 35(1):26-36. PubMed ID: 19595713
[TBL] [Abstract][Full Text] [Related]
18. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
[TBL] [Abstract][Full Text] [Related]
19. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.
Gallardo A; Lerma E; Escuin D; Tibau A; Muñoz J; Ojeda B; Barnadas A; Adrover E; Sánchez-Tejada L; Giner D; Ortiz-Martínez F; Peiró G
Br J Cancer; 2012 Apr; 106(8):1367-73. PubMed ID: 22454081
[TBL] [Abstract][Full Text] [Related]
20. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
Lee H; Akita RW; Sliwkowski MX; Maihle NJ
Cancer Res; 2001 Jun; 61(11):4467-73. PubMed ID: 11389077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
